Psychiatric treatment considerations with direct acting antivirals in hepatitis C
Despite recent advances in hepatitis C (HCV) treatment, specifically the addition of direct acting antivirals (DAAs), pegylated interferon-alpha remains the backbone of HCV therapy. Therefore, the impact of DAAs on the management of co-morbid psychiatric illness and neuropsychiatric sequalae remains...
Gespeichert in:
| Veröffentlicht in: | BMC gastroenterology 2013-05, Vol.13 (1), p.86-86, Article 86 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 86 |
|---|---|
| container_issue | 1 |
| container_start_page | 86 |
| container_title | BMC gastroenterology |
| container_volume | 13 |
| creator | Sockalingam, Sanjeev Tseng, Alice Giguere, Pierre Wong, David |
| description | Despite recent advances in hepatitis C (HCV) treatment, specifically the addition of direct acting antivirals (DAAs), pegylated interferon-alpha remains the backbone of HCV therapy. Therefore, the impact of DAAs on the management of co-morbid psychiatric illness and neuropsychiatric sequalae remains an ongoing concern during HCV therapy. This paper provides a review of the neuropsychiatric adverse effects of DAAs and drug-drug interactions (DDIs) between DAAs and psychiatric medications.
We conducted a Pubmed search using relevant search terms and hand searched reference lists of related review articles. In addition, we searched abstracts for major hepatology conferences and contacted respective pharmaceutical companies for additional studies.
Limited data is available on the neuropsychiatric adverse effects of DAAs; however, data from major clinical trials suggest that DAAs have minimal neuropsychiatric risk. DAAs can potentially interact with a variety of psychotropic agents via cytochrome P450 and p-glycoprotein interactions. Triazolam, oral midazolam, St. John's Wort, carbamazepine and pimozide, are contraindicated with DAAs. DDIs between DAAs and antidepressants, anxiolytics, hypnotics, mood stabilizers, antipsychotics and treatments for opioid dependence are summarized.
Although DAAs do not add significant neuropsychiatric risk, the potential for DDIs is high. Consideration of DDIs is paramount to improving medication adherence and mitigating adverse effects during HCV therapy. |
| doi_str_mv | 10.1186/1471-230X-13-86 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3658966</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A534585976</galeid><sourcerecordid>A534585976</sourcerecordid><originalsourceid>FETCH-LOGICAL-b605t-1c394f35528a419a96b1426f362eaa8a3285d8ee9698216aceef933f43541d003</originalsourceid><addsrcrecordid>eNp1Uk1vFDEMHSEQ_YAzNzQSFy7TTuJJJrkgtasWkCoVJJC4RdmMZ9fVzmRJskX9981oy9JFrXKwZT8_2y8uinesPmFMyVPWtKziUP-qGFRKvigOd5GXj_yD4ijGm7pmreLwujjgIFvORXNYfP8W79ySbArkyhTQpgHHVDo_Ruow2ETZK_9QWpYdBXSptC7RuCjtmOiWgl3FksZyiesMTRTL2ZviVZ-j-PbBHhc_Ly9-zL5UV9efv87Orqq5rEWqmAPd9CAEV7Zh2mo5Zw2XPUiO1ioLXIlOIWqpFWfSOsReA_QNiIZ1dQ3Hxact73ozH7Bzeew8jVkHGmy4M96S2c-MtDQLf2tACqWlzATnW4I5-WcI9jPOD2aS1EySGgZGTSQfH6YI_vcGYzIDRYerlR3Rb2LGa6l02_I2Qz_8B73xmzBmjTKXEFADcP0PtbArNDT2Pvd2E6k5E9AIJXQ7tT15ApVfhwPlz8Oecnyv4HRb4IKPMWC_25PVZjqlJzZ7_1jfHf7v7cA9CVXEFw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1355303329</pqid></control><display><type>article</type><title>Psychiatric treatment considerations with direct acting antivirals in hepatitis C</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Springer Nature OA Free Journals</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>Sockalingam, Sanjeev ; Tseng, Alice ; Giguere, Pierre ; Wong, David</creator><creatorcontrib>Sockalingam, Sanjeev ; Tseng, Alice ; Giguere, Pierre ; Wong, David</creatorcontrib><description>Despite recent advances in hepatitis C (HCV) treatment, specifically the addition of direct acting antivirals (DAAs), pegylated interferon-alpha remains the backbone of HCV therapy. Therefore, the impact of DAAs on the management of co-morbid psychiatric illness and neuropsychiatric sequalae remains an ongoing concern during HCV therapy. This paper provides a review of the neuropsychiatric adverse effects of DAAs and drug-drug interactions (DDIs) between DAAs and psychiatric medications.
We conducted a Pubmed search using relevant search terms and hand searched reference lists of related review articles. In addition, we searched abstracts for major hepatology conferences and contacted respective pharmaceutical companies for additional studies.
Limited data is available on the neuropsychiatric adverse effects of DAAs; however, data from major clinical trials suggest that DAAs have minimal neuropsychiatric risk. DAAs can potentially interact with a variety of psychotropic agents via cytochrome P450 and p-glycoprotein interactions. Triazolam, oral midazolam, St. John's Wort, carbamazepine and pimozide, are contraindicated with DAAs. DDIs between DAAs and antidepressants, anxiolytics, hypnotics, mood stabilizers, antipsychotics and treatments for opioid dependence are summarized.
Although DAAs do not add significant neuropsychiatric risk, the potential for DDIs is high. Consideration of DDIs is paramount to improving medication adherence and mitigating adverse effects during HCV therapy.</description><identifier>ISSN: 1471-230X</identifier><identifier>EISSN: 1471-230X</identifier><identifier>DOI: 10.1186/1471-230X-13-86</identifier><identifier>PMID: 23672254</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Analysis ; Antidepressants ; Antiviral agents ; Antiviral Agents - adverse effects ; Antiviral Agents - therapeutic use ; Complications and side effects ; Contraindications ; Drug Interactions ; Drug therapy ; Gastroenterology ; Hepatitis ; Hepatitis C ; Hepatitis C - complications ; Hepatitis C - drug therapy ; Hepatitis C virus ; HIV ; Human immunodeficiency virus ; Humans ; Medication Adherence ; Mental disorders ; Mental Disorders - chemically induced ; Mental Disorders - complications ; Mental Disorders - drug therapy ; Mental illness ; Oligopeptides - adverse effects ; Patient compliance ; Proline - adverse effects ; Proline - analogs & derivatives ; Psychotropic Drugs - therapeutic use</subject><ispartof>BMC gastroenterology, 2013-05, Vol.13 (1), p.86-86, Article 86</ispartof><rights>COPYRIGHT 2013 BioMed Central Ltd.</rights><rights>2013 Sockalingam et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2013 Sockalingam et al.; licensee BioMed Central Ltd. 2013 Sockalingam et al.; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b605t-1c394f35528a419a96b1426f362eaa8a3285d8ee9698216aceef933f43541d003</citedby><cites>FETCH-LOGICAL-b605t-1c394f35528a419a96b1426f362eaa8a3285d8ee9698216aceef933f43541d003</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658966/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658966/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23672254$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sockalingam, Sanjeev</creatorcontrib><creatorcontrib>Tseng, Alice</creatorcontrib><creatorcontrib>Giguere, Pierre</creatorcontrib><creatorcontrib>Wong, David</creatorcontrib><title>Psychiatric treatment considerations with direct acting antivirals in hepatitis C</title><title>BMC gastroenterology</title><addtitle>BMC Gastroenterol</addtitle><description>Despite recent advances in hepatitis C (HCV) treatment, specifically the addition of direct acting antivirals (DAAs), pegylated interferon-alpha remains the backbone of HCV therapy. Therefore, the impact of DAAs on the management of co-morbid psychiatric illness and neuropsychiatric sequalae remains an ongoing concern during HCV therapy. This paper provides a review of the neuropsychiatric adverse effects of DAAs and drug-drug interactions (DDIs) between DAAs and psychiatric medications.
We conducted a Pubmed search using relevant search terms and hand searched reference lists of related review articles. In addition, we searched abstracts for major hepatology conferences and contacted respective pharmaceutical companies for additional studies.
Limited data is available on the neuropsychiatric adverse effects of DAAs; however, data from major clinical trials suggest that DAAs have minimal neuropsychiatric risk. DAAs can potentially interact with a variety of psychotropic agents via cytochrome P450 and p-glycoprotein interactions. Triazolam, oral midazolam, St. John's Wort, carbamazepine and pimozide, are contraindicated with DAAs. DDIs between DAAs and antidepressants, anxiolytics, hypnotics, mood stabilizers, antipsychotics and treatments for opioid dependence are summarized.
Although DAAs do not add significant neuropsychiatric risk, the potential for DDIs is high. Consideration of DDIs is paramount to improving medication adherence and mitigating adverse effects during HCV therapy.</description><subject>Analysis</subject><subject>Antidepressants</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - adverse effects</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Complications and side effects</subject><subject>Contraindications</subject><subject>Drug Interactions</subject><subject>Drug therapy</subject><subject>Gastroenterology</subject><subject>Hepatitis</subject><subject>Hepatitis C</subject><subject>Hepatitis C - complications</subject><subject>Hepatitis C - drug therapy</subject><subject>Hepatitis C virus</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Medication Adherence</subject><subject>Mental disorders</subject><subject>Mental Disorders - chemically induced</subject><subject>Mental Disorders - complications</subject><subject>Mental Disorders - drug therapy</subject><subject>Mental illness</subject><subject>Oligopeptides - adverse effects</subject><subject>Patient compliance</subject><subject>Proline - adverse effects</subject><subject>Proline - analogs & derivatives</subject><subject>Psychotropic Drugs - therapeutic use</subject><issn>1471-230X</issn><issn>1471-230X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp1Uk1vFDEMHSEQ_YAzNzQSFy7TTuJJJrkgtasWkCoVJJC4RdmMZ9fVzmRJskX9981oy9JFrXKwZT8_2y8uinesPmFMyVPWtKziUP-qGFRKvigOd5GXj_yD4ijGm7pmreLwujjgIFvORXNYfP8W79ySbArkyhTQpgHHVDo_Ruow2ETZK_9QWpYdBXSptC7RuCjtmOiWgl3FksZyiesMTRTL2ZviVZ-j-PbBHhc_Ly9-zL5UV9efv87Orqq5rEWqmAPd9CAEV7Zh2mo5Zw2XPUiO1ioLXIlOIWqpFWfSOsReA_QNiIZ1dQ3Hxact73ozH7Bzeew8jVkHGmy4M96S2c-MtDQLf2tACqWlzATnW4I5-WcI9jPOD2aS1EySGgZGTSQfH6YI_vcGYzIDRYerlR3Rb2LGa6l02_I2Qz_8B73xmzBmjTKXEFADcP0PtbArNDT2Pvd2E6k5E9AIJXQ7tT15ApVfhwPlz8Oecnyv4HRb4IKPMWC_25PVZjqlJzZ7_1jfHf7v7cA9CVXEFw</recordid><startdate>20130514</startdate><enddate>20130514</enddate><creator>Sockalingam, Sanjeev</creator><creator>Tseng, Alice</creator><creator>Giguere, Pierre</creator><creator>Wong, David</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7U9</scope><scope>5PM</scope></search><sort><creationdate>20130514</creationdate><title>Psychiatric treatment considerations with direct acting antivirals in hepatitis C</title><author>Sockalingam, Sanjeev ; Tseng, Alice ; Giguere, Pierre ; Wong, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b605t-1c394f35528a419a96b1426f362eaa8a3285d8ee9698216aceef933f43541d003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Analysis</topic><topic>Antidepressants</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - adverse effects</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Complications and side effects</topic><topic>Contraindications</topic><topic>Drug Interactions</topic><topic>Drug therapy</topic><topic>Gastroenterology</topic><topic>Hepatitis</topic><topic>Hepatitis C</topic><topic>Hepatitis C - complications</topic><topic>Hepatitis C - drug therapy</topic><topic>Hepatitis C virus</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Medication Adherence</topic><topic>Mental disorders</topic><topic>Mental Disorders - chemically induced</topic><topic>Mental Disorders - complications</topic><topic>Mental Disorders - drug therapy</topic><topic>Mental illness</topic><topic>Oligopeptides - adverse effects</topic><topic>Patient compliance</topic><topic>Proline - adverse effects</topic><topic>Proline - analogs & derivatives</topic><topic>Psychotropic Drugs - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sockalingam, Sanjeev</creatorcontrib><creatorcontrib>Tseng, Alice</creatorcontrib><creatorcontrib>Giguere, Pierre</creatorcontrib><creatorcontrib>Wong, David</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Virology and AIDS Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMC gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sockalingam, Sanjeev</au><au>Tseng, Alice</au><au>Giguere, Pierre</au><au>Wong, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Psychiatric treatment considerations with direct acting antivirals in hepatitis C</atitle><jtitle>BMC gastroenterology</jtitle><addtitle>BMC Gastroenterol</addtitle><date>2013-05-14</date><risdate>2013</risdate><volume>13</volume><issue>1</issue><spage>86</spage><epage>86</epage><pages>86-86</pages><artnum>86</artnum><issn>1471-230X</issn><eissn>1471-230X</eissn><abstract>Despite recent advances in hepatitis C (HCV) treatment, specifically the addition of direct acting antivirals (DAAs), pegylated interferon-alpha remains the backbone of HCV therapy. Therefore, the impact of DAAs on the management of co-morbid psychiatric illness and neuropsychiatric sequalae remains an ongoing concern during HCV therapy. This paper provides a review of the neuropsychiatric adverse effects of DAAs and drug-drug interactions (DDIs) between DAAs and psychiatric medications.
We conducted a Pubmed search using relevant search terms and hand searched reference lists of related review articles. In addition, we searched abstracts for major hepatology conferences and contacted respective pharmaceutical companies for additional studies.
Limited data is available on the neuropsychiatric adverse effects of DAAs; however, data from major clinical trials suggest that DAAs have minimal neuropsychiatric risk. DAAs can potentially interact with a variety of psychotropic agents via cytochrome P450 and p-glycoprotein interactions. Triazolam, oral midazolam, St. John's Wort, carbamazepine and pimozide, are contraindicated with DAAs. DDIs between DAAs and antidepressants, anxiolytics, hypnotics, mood stabilizers, antipsychotics and treatments for opioid dependence are summarized.
Although DAAs do not add significant neuropsychiatric risk, the potential for DDIs is high. Consideration of DDIs is paramount to improving medication adherence and mitigating adverse effects during HCV therapy.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>23672254</pmid><doi>10.1186/1471-230X-13-86</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1471-230X |
| ispartof | BMC gastroenterology, 2013-05, Vol.13 (1), p.86-86, Article 86 |
| issn | 1471-230X 1471-230X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3658966 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Springer Nature OA Free Journals; PubMed Central; SpringerLink Journals - AutoHoldings |
| subjects | Analysis Antidepressants Antiviral agents Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Complications and side effects Contraindications Drug Interactions Drug therapy Gastroenterology Hepatitis Hepatitis C Hepatitis C - complications Hepatitis C - drug therapy Hepatitis C virus HIV Human immunodeficiency virus Humans Medication Adherence Mental disorders Mental Disorders - chemically induced Mental Disorders - complications Mental Disorders - drug therapy Mental illness Oligopeptides - adverse effects Patient compliance Proline - adverse effects Proline - analogs & derivatives Psychotropic Drugs - therapeutic use |
| title | Psychiatric treatment considerations with direct acting antivirals in hepatitis C |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T09%3A26%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Psychiatric%20treatment%20considerations%20with%20direct%20acting%20antivirals%20in%20hepatitis%20C&rft.jtitle=BMC%20gastroenterology&rft.au=Sockalingam,%20Sanjeev&rft.date=2013-05-14&rft.volume=13&rft.issue=1&rft.spage=86&rft.epage=86&rft.pages=86-86&rft.artnum=86&rft.issn=1471-230X&rft.eissn=1471-230X&rft_id=info:doi/10.1186/1471-230X-13-86&rft_dat=%3Cgale_pubme%3EA534585976%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1355303329&rft_id=info:pmid/23672254&rft_galeid=A534585976&rfr_iscdi=true |